Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades.
Hopkins BD, Qian DC, Xu KM, McCook-Veal A, Switchenko J, Hartsell LM, Cimmino CB, Joshi SS, Narayan V, Master VA, Nazha B, Carthon BC, Bilen MA, Kucuk O, Shelton JW, Patel PR, Jani AB, Remick JS, Eng TY. Hopkins BD, et al. Among authors: jani ab. Clin Genitourin Cancer. 2024 Nov 28;23(1):102276. doi: 10.1016/j.clgc.2024.102276. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39709687 No abstract available.
Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy.
Sebastian NT, Goyal S, Liu Y, Dhere V, Jani AB, Hershatter B, Patel PR, Shelton JW, Hanasoge S, Godette KD, Patel SA. Sebastian NT, et al. Among authors: jani ab. J Contemp Brachytherapy. 2024 Aug;16(4):268-272. doi: 10.5114/jcb.2024.143130. Epub 2024 Sep 12. J Contemp Brachytherapy. 2024. PMID: 39628817 Free PMC article.
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, Jani AB, Cury FL, Hudes RS, Michalski JM, Hartford AC, Song D, Citrin DE, Karrison TG, Sandler HM, Feng FY, Efstathiou JA. Dahl DM, et al. Among authors: jani ab. J Clin Oncol. 2024 Dec;42(34):4095-4102. doi: 10.1200/JCO.23.02510. Epub 2024 Sep 3. J Clin Oncol. 2024. PMID: 39226514 Clinical Trial.
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial.
Coen JJ, Rodgers JP, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou J, Jani AB, Kucuk O, Souhami L, Pugh SL, Sandler HM, Shipley WU. Coen JJ, et al. Among authors: jani ab. Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):153-161. doi: 10.1016/j.ijrobp.2024.08.007. Epub 2024 Aug 13. Int J Radiat Oncol Biol Phys. 2025. PMID: 39147209 Clinical Trial.
Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study.
Lowentritt BH, Jani AB, Helfand BT, Uchio EM, Morris MA, Michalski JM, Chau A, Davis P, Chapin BF, Schuster DM; SPOTLIGHT Study Group. Lowentritt BH, et al. Among authors: jani ab. Adv Radiat Oncol. 2024 May 1;9(8):101532. doi: 10.1016/j.adro.2024.101532. eCollection 2024 Aug. Adv Radiat Oncol. 2024. PMID: 39104875 Free PMC article.
Biochemical Relapse-Free Survival in Postprostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed-Only Radiation: Post Hoc Analysis of a Prospective Randomized Trial.
Dhere VR, Schuster DM, Goyal S, Schreibmann E, Hershatter BW, Patel SA, Shelton JW, Hanasoge S, Patel PR, Sebastian NT, Adediran OA, Lawal IO, Jani AB. Dhere VR, et al. Among authors: jani ab. Pract Radiat Oncol. 2024 Nov-Dec;14(6):e492-e499. doi: 10.1016/j.prro.2024.05.011. Epub 2024 Jul 20. Pract Radiat Oncol. 2024. PMID: 39032598 Clinical Trial.
225 results